Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial

BACKGROUND: Both enzalutamide and abiraterone have demonstrated improved radiographic progression-free and overall survival for castration-resistant prostate cancer (CRPC) compared with placebo controls before docetaxel treatment in phase III studies. These oral agents target androgen and androgen r...

Descripción completa

Detalles Bibliográficos
Autores principales: Izumi, Kouji, Mizokami, Atsushi, Namiki, Mikio, Inoue, Shogo, Tanaka, Nobumichi, Yoshio, Yuko, Ishibashi, Kei, Kamiyama, Manabu, Kawai, Noriyasu, Enokida, Hideki, Shima, Takashi, Takahara, Shizuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635584/
https://www.ncbi.nlm.nih.gov/pubmed/29017493
http://dx.doi.org/10.1186/s12885-017-3661-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635584/
https://www.ncbi.nlm.nih.gov/pubmed/29017493
http://dx.doi.org/10.1186/s12885-017-3661-2

Ejemplares similares